新疆医科大学学报

目的 探讨尤瑞克林联合依达拉奉治疗脑梗死的效果及对患者脑神经功能的影响。方法 选取2024年1月至2025年1月在如皋市人民医院就诊的162例脑梗死患者为研究对象，采用随机数字表法分为联合组和单药组，各81例，单药组给予依达拉奉治疗，联合组在单药组治疗基础上加用尤瑞克林治疗，均治疗2周。比较两组治疗前后美国国立卫生研究院卒中量表(National institute of health stroke scale, NIHSS)评分、搏动指数(Pulsatility index, PI)、脑血管储备能力(Cerebrovascular reserve capacity, CVR)、炎性指标[肿瘤坏死因子α(Tumor necrosis factor α,TNF-α),白介素-6(Interleukin 6,IL-6)]、血管内皮功能[内皮素-1(Endothelin 1,ET-1),一氧化氮(Nitric oxide, NO)]、血液流变学指标(全血黏度)、氧化应激指标[谷胱甘肽过氧化物酶(Glutathione peroxidase, GSH-Px),过氧化氢酶(Cavenger enzymes, CAT)]。结果 与治疗前比较，治疗后两组CVR、NO、CAT及GSH-Px水平均升高，且联合组高于单药组(P<0.05)。与治疗前比较，治疗后两组ET-1、PI、TNF-ɑ、IL-6、全血黏度及NIHSS评分均降低，且联合组低于单药组(P<0.05)。联合组治疗总有效率为97.53%,高于单药组的90.12%,差异有统计学意义(P<0.05)。结论 尤瑞克林联合依达拉奉可有效改善脑梗死可改善患者脑神经功能，临床疗效优于单一依达拉奉治疗。

Objective This study investigated the efficacy of urinary kallidinogenase in combination with edaravone for cerebral infarction and its effected on patients' neurological functions. Methods A study was conducted on 162 cerebral infarction patients treated in thehospital from January 2024 to January 2025. Participants were randomly assigned to a combined therapy group and a monotherapy group(81 cases each) using a random number table. The monotherapy group received edaravone treatment, while the combined group received edaravone urinary kallidinogenase in addition to monotherapy, with both groups receiving treatment for 2 weeks. The study compared changes in the following parameters between the 2 groups before and after thetreatment: National Institutes of Health Stroke Scale(NIHSS), pulsatility index(PI), cerebrovascular reserve capacity(CVR), inflammatory markers [Tumor necrosis factor α(TNF-α), Interleukin 6(IL-6)], vascular endothelial function [Endothelin 1(ET-1), Nitric oxide(NO)], hemorheological parameters [whole blood viscosity] and oxidative stress indicators [Glutathione peroxidase(GSH-Px), Cavenger enzymes(CAT)]. Results Compared with pre-treatment levels, both groups showed increased CVR, NO, CAT and GSH-Px levels after the treatment, with the combination group demonstrating higher values than the monotherapy group(P<0.05). Conversely, ET-1, PI, TNF-α, IL-6, whole blood viscosity and NIHSS scores decreased in both groups post-treatment, and these values were lower in the combination group compared to the monotherapy group(P<0.05). The overall treatment efficacy rate in the combination group was 97.53%, which was higher than the 90.12% observed in the monotherapy group, and this difference was statistically significant(P<0.05). Conclusion The combination of urinary kallidinogenase with edaravone can effectively improve cerebral infarction and improve the neurological function of thepatients, and the clinical efficacy is better than the single edaravone treatment.